August 23rd 2021
A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.
David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
August 16th 2021
Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.
A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.
August 9th 2021
Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.
A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
August 2nd 2021
Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
July 26th 2021
Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.
Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.
July 19th 2021
David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.
A panel of experts explain how they approach CNS prophylaxis in DLBCL.
July 12th 2021
Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.
Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.
April 19th 2021
A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.
April 12th 2021
Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.
Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.
April 5th 2021
Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).